Recent Updates
Recently added Catalysts
IOVA Negative Sentiment Score: 25/100

IOVANCE BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Iovance Biotherapeutics, Inc. - IOVA

Key Takeaway: Iovance Biotherapeutics is facing a class action lawsuit for failing to disclose material information during the class period of May 9, 2024, to May 8, 2025. The lawsuit comes after a significant revenue drop was announced, including a 40% reduction in full-year revenue guidance for 2025. Following the announcement on May 8, 2025, shares fell by 44.8%, highlighting investor concern. ClaimsFiler has alerted investors of the approaching lead plaintiff application deadline on July 15, 2025.

Market Sentiment Analysis

CONCERNS & RISKS

  • Iovance experienced a significant decline in revenue guidance, cutting it by 40% for the fiscal year 2025.
  • The company's quarterly product revenue fell sharply from $73.7M to $49.3M.
  • Shares of Iovance dropped 44.8% following the poor financial results announcement.
  • The class action lawsuit is based on allegations of failing to disclose material information.

Full Press Release Details

NEW ORLEANS, May 28, 2025 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until July 15, 2025 to file lead plaintiff applications in a securities class action lawsuit against Iovance Biotherapeutics, Inc. (“Iovance” or the “Company”) (NasdaqGM: IOVA), if they purchased the Company’s securities between May 9, 2024 and May 8, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Iovance investors should visit us at https://claimsfiler.com/cases/nasdaq-iova/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options.
Iovance and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On May 8, 2025, the Company announced its 1Q 2025 financial results, disclosing a quarterly total product revenue of $49.3M, a significant decline from the prior quarter’s $73.7M, as well as a 40% cut to its full fiscal year 2025 total product revenue guidance from a range of $450M - $475M to $250M - $300M. Further, the Company revealed it was “revising full-year 2025 revenue guidance to reflect recent launch dynamics” of Amtagvi and that “[t]he updated forecast considers experience with ATC [authorized treatment center] growth trajectories and treatment timelines for new ATCs.”
On this news, the price of Iovance’s shares fell 44.8%, from $1.42 per share to close at $1.75 per share on May 9, 2025, on unusually heavy trading volume.
The case is Farberov v. Iovance Biotherapeutics, Inc., et al., Case No. 25-cv-4199.
ClaimsFiler has a single mission: to serve as the information source to help retail investors recover their share of billions of dollars from securities class action settlements. At ClaimsFiler.com, investors can: (1) register for free to gain access to information and settlement websites for various securities class action cases so they can timely submit their own claims; (2) upload their portfolio transactional data to be notified about relevant securities cases in which they may have a financial interest; and (3) submit inquiries to the Kahn Swick & Foti, LLC law firm for free case evaluations.
To learn more about ClaimsFiler, visit www.claimsfiler.com.

Tags

Frequently Asked Questions

What is the deadline for filing lead plaintiff applications?

The deadline to file lead plaintiff applications is July 15, 2025.

What company is involved in the class action lawsuit?

The class action lawsuit involves Iovance Biotherapeutics, Inc.

When did the Class Period for this lawsuit start?

The Class Period started on May 9, 2024.

What caused the shares of Iovance to drop significantly?

Shares fell due to disclosed revenue declines and guidance cuts on May 8, 2025.

How can investors learn more about this lawsuit?

Investors can visit https://claimsfiler.com/cases/nasdaq-iova/ for more information.

Last updated: May 29, 2025